Jonsson Comprehensive Cancer Center
🇺🇸United States
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT01070186
Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer
Completed
- Conditions
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 167
- Registration Number
- NCT01059513
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT01051037
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01051609
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01029925
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT01013285
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, University of California, Los Angeles (UCLA), Los Angeles, California, United States
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT01005472
- Locations
- 🇺🇸
University of California Los Angeles (UCLA), Los Angeles, California, United States
Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants
Not Applicable
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00999557
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00998010
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00955591
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
© Copyright 2024. All Rights Reserved by MedPath